Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)
About
The National Institute on Deafness and other Communication Disorders (NIDCD) intends to re-issue a Notice of Funding Opportunity (NOFO, prior funding opportunity RFA-DC-24-008 to solicit applications for research on early-stage dissemination and implementation (D&I) in the NIDCD mission areas of hearing, balance, taste, smell, voice, speech, and language. Much research is devoted to developing evidence-based innovations (EBIs) that improve a person"s health and quality of life. To impact people"s lives, EBIs need to be adopted in clinical practice and everyday life. Unfortunately, wide-scale adoption of EBIs is lengthy and rare. Dissemination and implementation (D&I) science is the field of research that seeks to close the gap between research and practice. Dissemination research is defined as the scientific study of the targeted distribution of information and materials about EBI to a specific audience (e. g., practitioners, patients, policymakers). The intent is to understand how best to communicate and integrate knowledge associated with a given EBI. Implementation Science refers to a broader array of active and planned efforts to integrate evidence into practice. Implementation research focuses on understanding why clinical and community settings are not adopting and sustaining a particular EBI. In turn, implementation research uses this understanding of barriers and facilitators to develop and evaluate different strategies (or collections of strategies) to increase adopti.
The Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional) grant, issued by the National Institute on Deafness and Other Communication Disorders (NIDCD), funds researchers developing strategies to bridge the gap between evidence-based innovations (EBIs) and real-world clinical practice. This program is ideal for researchers, academic institutions, and healthcare organizations working in hearing, balance, taste, smell, voice, speech, and language disorders who want to accelerate the adoption of proven interventions. The grant supports dissemination research—studying how to effectively communicate and distribute information about EBIs to practitioners, patients, and policymakers—and implementation research, which examines barriers and facilitators to clinical adoption and develops strategies to increase sustained use. If your organization has developed promising communication disorder treatments or interventions but struggles with implementation challenges, this grant provides resources to conduct early-stage research that could transform how EBIs reach those who need them. The program welcomes domestic and international applicants, including non-U.S. organizations and foreign components of U.S. institutions, making it accessible to global research teams committed to improving health outcomes in communication disorders.
Funding Facts
● Applications openDeadline
June 17, 2027
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by cycle—contact NIDCD for specific amounts
Deadline
2027-06-17
Grant Type
federal
Application Cycle
Annual with specific deadline (June 17, 2027 for current cycle)
Best For
Researchers and institutions focused on dissemination and implementation of evidence-based communication disorder treatments; academic medical centers; speech-language pathology organizations; audiology programs; international research teams
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no l
Frequently Asked Questions
Who is eligible for Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)?
Eligibility includes both domestic and international applicants. U.S. organizations, non-U.S. entities, and foreign components of U.S. organizations may apply. For complete eligibility requirements, including institutional qualifications, researcher credentials, and specific restrictions, refer to Section III of the official Notice of Funding Opportunity (NOFO) or contact the NIDCD directly through the NIH website.
How much funding does Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional) provide?
Specific funding amounts are not provided in the available information. Award amounts typically vary by funding cycle and project scope. Visit the official NIDCD funding opportunity announcement or contact the program officer for current funding ranges and budget limits for this grant cycle.
How do I apply for Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)?
Applications are submitted through the NIH grants application system (Grants.gov). Review the official NOFO for detailed instructions, required forms, and submission deadlines. You will need to develop a research proposal outlining your dissemination or implementation research strategy, specific aims, methodology, and expected impact on communication disorders practice. Consult with your institutional research office and the NIDCD program officer before submitting.
What can Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional) funding be used for?
Funding supports early-stage dissemination and implementation research in NIDCD mission areas including hearing, balance, taste, smell, voice, speech, and language disorders. This includes studies examining how to effectively communicate evidence-based innovations to target audiences, identifying barriers and facilitators to clinical adoption, developing implementation strategies, and evaluating approaches to increase sustained use of EBIs in clinical and community settings. The grant is optional for clinical trials, so both trial and non-trial research may be supported.
Last updated: July 5, 2026